Systematic review: Safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza

Annals of Internal Medicine

Volumn 151, Issue 7, 2009, Pages 464-473

  Khazeni, Nayer ^a   Bravata, Dena M ^b   Holty, Jon Erik C ^a   Uyeki, Timothy M ^c   Stave, Christopher D ^a   Gould, Michael K ^d  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ABDOMINAL PAIN; ANEMIA; ARTHRALGIA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; HEADACHE; HUMAN; HUMERUS FRACTURE; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INSOMNIA; LYMPHOCYTOPENIA; NAUSEA; NAUSEA AND VOMITING; PANDEMIC; PERITONSILLAR ABSCESS; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; URTICARIA; VOMITING;

EID: 70349748593     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-151-7-200910060-00143     Document Type: Review

References (79)

1. World Health Organization. Influenza (Seasonal). Fact sheet no. 211. 2009. Accessed at www.who.int/mediacentre/factsheets/fs211/en/ on 17 June 2009.
2. Potter CW. A history of influenza. J Appl Microbiol. 2001;91:572-579 [PMID: 11576290]
3. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002;76:105-115 [PMID: 11875246]
4. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605-2615 [PMID: 19423869]
5. World Health Organization. Global Alert and Response (EPR): Pandemic (H1N1) 2009. Accessed at www.who.int/csr/disease/swineflu/en/index.html on 18 July 2009.
6. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis. 2006;194 Suppl 2:S111-8. [PMID: 17163383]
7. Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM. Immune response to influenza vaccination in a large healthy elderly population. Vaccine. 1999;17:82-94. [PMID: 10078611] (Pubitemid 28470736)
8. Kimball P, Verbeke S, Flattery M, Rhodes C, Tolman D. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation. 2000;69:2449-2451 [PMID: 10868658] (Pubitemid 30409021)
9. Mazzone PJ, Mossad SB, Mawhorter SD, Mehta AC, Schilz RJ, Maurer JR. The humoral immune response to influenza vaccination in lung transplant patients. Eur Respir J. 2001;18:971-976 [PMID: 11829104]
10. Duchini A, Hendry RM, Nyberg LM, Viernes ME, Pockros PJ. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl. 2001;7:311-313 [PMID: 11303290] (Pubitemid 32331534)
11. World Health Organization. Pandemic influenza draft protocol for rapid response and containment. 17 March 2006. Accessed at www.who.int/csr/disease /avian-influenza/guidelines/pandemicfluprotocol-17.03a.pdf on 17 June 2009.
12. Enserink M. Oseltamivir becomes plentiful-but still not cheap. Science. 2006;312:382-383 [PMID: 16627733]
13. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for prophylaxis of type A influenza in nursing homes. Antimicrob Agents Chemother. 1995;39:2224-2228 [PMID: 8619572]
14. Lee C, Loeb M, Phillips A, Nesbitt J, Smith K, Fearon M, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control Hosp Epidemiol. 2000;21:700-704 [PMID: 11089653] (Pubitemid 30841251)
15. Peters PH Jr, Gravenstein S, Norwood P, De Bock V, Van Couter A, Gibbens M, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc. 2001;49:1025-1031 [PMID: 11555062] (Pubitemid 32801138)
16. Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis Rep. 2001;27:37-40. [PMID: 11260987]
17. Chik KW, Li CK, Chan PK, Shing MM, Lee V, Tam JS, et al. Oseltamivir prophylaxis during the influenza season in a paediatric cancer centre: prospective observational study. Hong Kong Med J. 2004;10:103-106 [PMID: 15075430] (Pubitemid 38477922)
18. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis. 2007;196:249-257 [PMID: 17570112] (Pubitemid 47047464)
19. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175-1181 [PMID: 16198766] (Pubitemid 41393595)
20. WHO Rapid Advice Guideline Panel on Avian Influenza. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007;7:21-31. [PMID: 17182341]
21. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284-3292 [PMID: 18625765]
22. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill. 2008;13. [PMID: 18445375]
23. Recommended composition of influenza virus vaccines for use in the 2009-2010 influenza season (northern hemisphere winter). Wkly Epidemiol Rec. 2009;84:65-72. [PMID: 19248288]
24. Centers for Disease Control and Prevention (CDC). Update: influenza activity-United States, September 28, 2008-January 31, 2009. MMWR Morb Mortal Wkly Rep. 2009;58:115-119 [PMID: 19214161]
25. Cheung CL, Rayner JM, Smith GJ, Wang P, Naipospos TS, Zhang J, et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis. 2006;193:1626-1629 [PMID: 16703504] (Pubitemid 43839465)
26. Hatakeyama S, Kawaoka Y. [The molecular basis of resistance to antiinfluenza drugs]. Nippon Rinsho. 2006;64:1845-1852 [PMID: 17037359]
27. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007;73:228-231 [PMID: 17112602] (Pubitemid 46273119)
28. New concerns about oseltamivir [Editorial]. Lancet. 2007;369:1056. [PMID: 17398285]
29. Russell S. Japan links Tamiflu to 2 teen suicides. San Francisco Chronicle. 15 November 2005. Accessed at www.sfgate.com/cgi-bin/article.cgi? file=/c/a/2005/11/15/MNG29FO9K71.DTL on 17 June 2009.
30. Centers for Disease Control and Prevention (CDC). Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep. 2009;58:433-435 [PMID: 19407738]
31. Rungrotmongkol T, Intharathep P, Malaisree M, Nunthaboot N, Kaiyawet N, Sompornpisut P, et al. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem Biophys Res Commun. 2009;385:390-394 [PMID: 19463784]
32. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197-201. [PMID: 19465683]
33. Roan S, Kaplan K. Decisions surround swine flu vaccine. Los Angeles Times. 29 April 2009. Accessed at www.latimes.com/features/health/la-sci-swine- vaccine29-2009apr29,0,4276069.story on 17 June 2009.
34. Counsell C. Formulating questions and locating primary studies for inclusion in systematic reviews. Ann Intern Med. 1997;127:380-387 [PMID: 9273830] (Pubitemid 27362747)
35. Meade MO, Richardson WS. Selecting and appraising studies for a systematic review. Ann Intern Med. 1997;127:531-537 [PMID: 9313021]
36. Kashiwagi S, Kudoh S, Watanabe A, Yoshimura I. [Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza-placebo-controlled double-blind multicenter phase III trial]. Kansenshogaku Zasshi. 2000;74:1062-1076 [PMID: 11193558]
37. Vander Stichele R. Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol. 1991;41:27-35. [PMID: 1838332]
38. Haynes RB, Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials. 1987;8:12-19 [PMID: 3568692] (Pubitemid 17040574)
39. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. [PMID: 8721797]
40. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326:1167-1170 [PMID: 12775614] (Pubitemid 36649048)
41. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-465 [PMID: 12533125] (Pubitemid 36119966)
42. Bentley JP, Thacker PG. The influence of risk and monetary payment on the research participation decision making process. J Med Ethics. 2004;30:293-298 [PMID: 15173366]
43. Roche Pharmaceuticals. Tamiflu [Package insert]. August 2008. Accessed at www.rocheusa.com/products/Tamiflu/PI.pdf on 17 June 2009.
44. GlaxoSmithKline Pharmaceuticals. Relenza [Package insert]. February 2008. Accessed at http://us.gsk.com/products/assets/us-relenza.pdf on 17 June 2009.
45. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement. 1960;20:37-46.
46. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558 [PMID: 12111919]
47. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455-463 [PMID: 10877304] (Pubitemid 30422636)
48. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101 [PMID: 7786990]
49. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med. 1999;341:1336-1343 [PMID: 10536125] (Pubitemid 29503572)
50. LaForce C, Man CY, Henderson FW, McElhaney JE, Hampel FC Jr, Bettis R, et al. Efficacy and safety of inhaled zanamivir in the prevention of influenza in community-dwelling, high-risk adult and adolescent subjects: a 28-day, multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2007;29:1579-90; discussion 1577-1578 [PMID: 17919541] (Pubitemid 47500131)
51. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA. 1999;282:31-35 [PMID: 10404908] (Pubitemid 29318929)
52. Webster A, Boyce M, Edmundson S, Miller I. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet. 1999;36 Suppl 1:51-58 [PMID: 10429840]
53. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57:1-60. [PMID: 18685555]
54. Centers for Disease Control and Prevention. Flu Activity & Surveillance. 1996-2009. Accessed at www.cdc.gov/flu/weekly/fluactivity.htm on 17 June 2009.
55. Kawado M, Hashimoto S, Murakami Y, Izumida M, Ohta A, Tada Y, et al. Annual and weekly incidence rates of influenza and pediatric diseases estimated from infectious disease surveillance data in Japan, 2002-2005. J Epidemiol. 2007;17 Suppl:S32-41. [PMID: 18239340]
56. MedWatch. The Clinical Impact of Adverse Drug Reporting. 1996. Accessed at www.fda.gov/downloads/Safety/MedWatch/UCM168505.pdf on 17 June 2009.
57. Lewis JA. Post-marketing surveillance: how many patients? Trends in Pharmacological Sciences. 1981;2:93-94
58. Sternberg S. Study: flu viruses growing resistant to key weapon Tamiflu. USA Today. 2 March 2009. Accessed at www.usatoday.com/news/health/2009-03-02- fluvirus-Tamifluresistant-N.htm on 17 June 2009.
59. Pandemic flu stockpiles are set to double, UK. Medical News Today. 30 January 2009. Accessed at www.medicalnewstoday.com/articles/137256.php on 17 June 2009.
60. Canada to change flu drugs in pandemic stockpile. The Canadian Press. 20 April 2009. Accessed at www.ctv.ca/servlet/ArticleNews/story/CTVNews /20090420/flu-drugs-090420/20090420?hub=Health on 17 June 2009.
61. Roos R. HHS advisors urge full speed on H1N1 vaccine production. 17 July 2009. Accessed at www.cidrap.umn.edu/cidrap/content/influenza/swineflunews/ jul1709board.html on 17 June 2009.
62. Diggory P, Fernandez C, Humphrey A, Jones V, Murphy M. Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial. BMJ. 2001;322:577-579 [PMID: 11238150] (Pubitemid 32234531)
63. Hall GH. Elderly people's technique in using dry powder inhalers. Zanamivir and unreason seem to go together [Letter]. BMJ. 2001;323:50. [PMID: 11464829]
64. World Health Organization. Influenza A (H1N1) virus resistance to oseltamivir. 2009. Accessed at www.who.int/csr/disease/influenza/oseltamivir- summary/en/index.html on 17 June 2009.
65. World Health Organization. Pandemic (H1N1) 2009 briefing note 1. Viruses resistant to oseltamivir (Tamiflu) identified. 2009. Accessed at www.who.int/csr/disease/swineflu/notes/h1n1-antiviral-resistance-20090708/en/ index.html on 17 June 2009.
66. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis. 2009;48 Suppl 1:S3-13. [PMID: 19067613]
67. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med. 2009;360:953-956 [PMID: 19258250]
68. Cheng PK, Leung TW, Ho EC, Leung PC, Ng AY, Lai MY, et al. Oseltamivir- and amantadine-resistant influenza viruses A (H1N1). Emerg Infect Dis. 2009;15:966-968 [PMID: 19523305]
69. Roche. A study of Tamiflu (oseltamivir) for the seasonal prophylaxis of influenza in immunocompromised patients (NV20235). Accessed at www.roche -trials.com/patient/trials/trial110709.html on 17 June 2009.
70. U.S. Department of Health and Human Services. Pandemic flu plan. Appendix D. Accessed at www.hhs.gov/pandemicflu/plan/appendixd.html on 17 June 2009.
71. ACIP of the Centers for Disease Control and Prevention. ACIP releases recommendations for use of live, attenuated influenza vaccine. Am Fam Physician. 2003;68:2275-2276 [PMID: 14677671]
72. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al, CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007;356:685-696 [PMID: 17301299]
73. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, et al, CAIV-T Asthma Study Group. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J. 2006;25:860-869 [PMID: 17006278]
74. Food and Drug Administration. FDA Amendments Act. 27 September 2007. Accessed at http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110-cong- public-laws&docid=f:publ085.110 on 17 June 2009.
75. U.S. Department of Health and Human Services. Community strategy for pandemic influenza mitigation. Accessed at http://pandemicflu.gov/plan/ community/commitigation.html#XVI on 17 June 2009.
76. Wright PF. Vaccine preparedness - are we ready for the next influenza pandemic? N Engl J Med. 2008;358:2540-2543 [PMID: 18550873]
77. The National Centre in HIV Epidemiology and Clinical Research National Health and Medical Research Council - Australia. A prospective study to examine the effectiveness and safety of neuraminidase inhibitors in volunteers who receive long-term prophylaxis against pandemic influenza: PIPET B. 2009. Accessed at http://clinicaltrials.gov/ct2/show/NCT00640211 on 17 June 2009.
78. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-1373 [PMID: 16192481]
79. Patrozou E, Mermel LA. Does influenza transmission occur from asymptomatic infection or prior to symptom onset? Public Health Rep. 2009;124:193-196 [PMID: 19320359]